Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Stocks in play: Cardiol Therapeutics Inc

Baystreet.ca - Baystreet - Tue Sep 10, 9:01AM CDT

Announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture, on Monday, November 18, at the American Heart Association Scientific Sessions 2024. Cardiol Therapeutics Inc shares T.CRDL are trading up $0.09 at $2.77.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).